$14.90
▲ +0.7% Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
Wall Street Analysts Predict a 121.36% Upside in Tenax Therapeutics (TENX): Here's What You Should Know
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Overview
52-week range
$5.34
$18
73% of range
Avg surprise (last 3)
+33.4%
Avg reaction (last 2)
+1.0%
100% positive
Latest IV / EM
390%
EM ±89.3% · $15 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.35 | $-0.40 | +12.5% | -25.0% | +1.8% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.40 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.27 | $-0.50 | +46.0% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.28 | $-0.48 | +41.7% | — | +0.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.19 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.83 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-3.12 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$0.38 | -$0.27 | -40.7% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-17M | — | $-17M | $-12M | $-11M | — | $-5M | $-4M |
| Net income | $-16M | — | $-16M | $-11M | $-10M | — | $-4M | $-4M |
| EPS (diluted) | $-0.35 | — | $-0.40 | $-0.27 | $-0.28 | — | $-0.19 | $-1.83 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $119M | — | $99M | $106M | $111M | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $123M | $104M | $103M | $106M | $112M | $97M | $100M | $11M |
| Total assets | $123M | $104M | $103M | $106M | $112M | $97M | $100M | $11M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $8M | $7M | $7M | $3M | $3M | $5M | $3M | $2M |
| Total equity | $115M | $97M | $96M | $103M | $109M | $92M | $97M | $9M |